Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

32.46
+0.55781.75%
Post-market: 32.460.00000.00%19:30 EDT
Volume:2K
Turnover:49.64K
Market Cap:41.39M
PE:- -
High:32.46
Open:32.27
Low:32.24
Close:31.90
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:0.40
T/O Rate:0.12%
Dividend:0.08
Dividend Rate:0.23%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

1s Could Offer Unexpected Relief from Back and Knee Pain, but Doctors Urge Caution

Dow Jones
·
Oct 08

Analysts’ Top Healthcare Picks: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Oct 08

RBC Lifts Price Target on Rhythm Pharmaceuticals to $159 From $155, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Oct 08

How to invest in healthcare stocks without picking the next Eli Lilly

Simply Wall St.
·
Oct 08

Rhythm Pharmaceuticals, Inc. : RBC Raises Target Price to $159 from $155

THOMSON REUTERS
·
Oct 08

Dow Falls Over 300 Points As Treasury Yields Surge: Investor Sentiment Weakens, Fear & Greed Index Remains In ‘Neutral’ Zone

Benzinga Earnings
·
Oct 08

Moderna Inc. Stock Rises 4.8%, Outperforms Peers

Dow Jones
·
Oct 08

Eli Lilly & Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 08

Eli Lilly and Co Stock (LLY) Moved Up by 3.94% on Oct 7: Facts Behind the Movement

TradingKey
·
Oct 08

Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis

TradingKey
·
Oct 08

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Oct 08

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

TIPRANKS
·
Oct 07

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

GlobeNewswire
·
Oct 07

Pharma Lobby Sues Trump Administration over Medicare Drug Price Cuts

Reuters
·
Oct 07

Eli Lilly is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Oct 07

What Eli Lilly Stock's First Line Jaypirca Approval Means For Shareholders

Simply Wall St.
·
Oct 07

Early notable gainers among liquid option names on October 7th

TIPRANKS
·
Oct 07

Morgan Stanley Adjusts Price Target on Eli Lilly to $1,430 From $1,419

MT Newswires Live
·
Oct 07

J.P. Morgan Remains a Buy on Gilead Sciences (GILD)

TIPRANKS
·
Oct 07

AlzeCure Pharma to Present at Redeye Neurology Day

Reuters
·
Oct 07